📬 Lung/Head and Neck/Thymoma Intelligence Digest — Week 2026-W29

Adjuvant ensartinib delivers ALINA-like DFS in resected ALK+ NSCLC while lung transplant shows striking early survival in refractory lung-limited stage IV NSCLC; TREASURE and ZEAL-1L are negative, and a B7-H3 ADC posts the first phase 3 OS win in relapsed SCLC.

⚡ TL;DR

📄 Publications

Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. — In stage II-IIIB, 24-month DFS was 86.4% with ensartinib vs 53.5% with placebo (HR 0.20)
Lung Transplant for Refractory Lung-Limited Stage IV Non-Small Cell Lung Cancer. — 1-year OS was 100% among transplant recipients vs 40.8% with medical management (absolute difference 59.2 points)
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial. — With durvalumab, baseline PPI use was associated with shorter OS (33.0 vs 57.9 months, HR 1.66)
Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320). — Median OS was numerically shorter with combination TRT (6.7 vs 13.4 months, HR 1.55)

🐦 Twitter / 🦋 Bluesky

ARTEMIS-008: first phase 3 OS win for a B7-H3 ADC in relapsed SCLC — Risvutatug rezetecan, a B7-H3 ADC, showed superior OS versus topotecan in relapsed SCLC
Update: PACIFIC post-hoc pulls in editorial voices on PPIs, antibiotics and the gut microbiome — With durvalumab, baseline PPI use was tied to shorter PFS (9.4 vs 17.2m, HR 1.57) and OS (33 vs 57.9m, HR 1.66), with no effect in placebo
ELEVATE: adjuvant ensartinib matches ALINA-level DFS in resected ALK+ NSCLC — In stage II-IIIB, 24-month DFS was 86.4% vs 53.5% with placebo (HR 0.20)
DREAM: lung transplant offers striking early survival in refractory lung-limited stage IV NSCLC — 1-year OS was 100% in transplant recipients vs 40.8% with medical management, a 59.2 percentage point difference
Ifebemtinib plus garsorasib delivers high response in first-line KRAS G12C NSCLC — First-line ifebemtinib plus garsorasib gave RR 82%, mPFS 22.3m, mOS 27.8m, with 24% grade 3+ TRAEs

Full details below ↓

📄 What's Being Published

Manuscripts:

Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. — Yue Dongsheng et al., N Engl J Med

In the stage II–IIIB population, 24-month DFS was 86.4% with ensartinib versus 53.5% with placebo (HR 0.20; 95% CI, 0.11–0.38; P<0.001). Across the overall patient population, 24-month DFS was 87.3% versus 57.2% (HR 0.20; 95% CI, 0.10–0.37; P<0.001). Grade 3 or higher adverse events occurred in 35.8% of patients receiving ensartinib — most commonly rash — compared with 18.2% on placebo.

Clinical bottom line: Adjuvant ensartinib for 24 months after chemotherapy dramatically extends disease-free survival in resected stage IB–IIIB ALK-positive NSCLC, reinforcing molecular testing in early-stage disease.

Read full article →

🔗 Also discussed on social media →

Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L). — Ramalingam Suresh S et al., J Thorac Oncol

In the CR/PR population (n=200 receiving niraparib-plus-pembrolizumab; n=201 receiving placebo-plus-pembrolizumab), median PFS was 5.55 months in both arms (HR 1.00; 95% CI, 0.79–1.27; 1-sided p=0.502). The addition of niraparib to pembrolizumab for maintenance therapy did not result in improved efficacy, and no new safety signals were detected.

Clinical bottom line: Adding niraparib to pembrolizumab maintenance produced no PFS benefit in advanced NSCLC, closing the door on this PARP-plus-checkpoint maintenance strategy.

Read full article →

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial. — Brunetti Leonardo et al., Lancet Oncol

In the durvalumab group, baseline PPI use was associated with shorter PFS (9.4 months [95% CI 7.6–13.7] vs 17.2 months [95% CI 15.4–23.2]; HR 1.57 [95% CI 1.28–1.93]; p<0.0001) and shorter OS (33.0 months [95% CI 21.9–46.7] vs 57.9 months [95% CI 48.7–not computable]; HR 1.66 [95% CI 1.30–2.13]; p<0.0001) compared with no PPI exposure. No corresponding difference was observed in the placebo arm.

Clinical bottom line: The published PACIFIC post-hoc draws in additional voices weighing gut-microbiome-modifying drugs, with StephenVLiu and an accompanying Lancet Oncology editorial from ASridharMD and ACortelliniMD calling for prospective, trial-embedded studies of PPI and antibiotic exposure in stage III NSCLC.

Read full article →

🔗 Also discussed on social media →

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer. — Huang Julian et al., Clin Cancer Res

MTAP is deleted in 13% of NSCLC, and MTAP two-copy deleted cancer cells are vulnerable to PRMT5 inhibitors under investigation. Patients with MTAPdel versus MTAPwt NSCLC had shorter PFS on anti-PD-(L)1 monotherapy (HR 1.70; 95% CI, 1.02–2.82; p=0.040) and on platinum doublet plus anti-PD-(L)1 therapy (HR 1.89; 95% CI, 1.20–2.97; p=0.006).

Clinical bottom line: MTAP-deleted NSCLC presents with more aggressive features and PD-L1 TPS <1%, and does worse on anti-PD-(L)1-based therapy, marking a subgroup that needs dedicated targeted approaches.

Read full article →

Impact of Prior Systemic Chemotherapy on Response to ROS1 Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. — Kashizaki Fumihiro et al., JCO Precis Oncol

Pooled ORR was 79% (95% CI, 72–84) in TKI-naïve cohorts versus 42% (95% CI, 32–51) in post-crizotinib cohorts. Among 11 TKI-naïve cohorts, prior systemic chemotherapy exposure was significantly and inversely associated with ORR (OR 0.33; P=.004).

Clinical bottom line: Prior chemotherapy is associated with lower response to ROS1-TKIs, supporting early use of ROS1-directed therapy when feasible.

Read full article →

Genomic Landscape and Clinical Impact of MTAP Loss in Driver-Positive NSCLC: Insights from a Large-Scale Real-World Chinese Cohort. — Wei Qianhui et al., J Thorac Oncol

MTAP loss was identified in 10.4% of the overall cohort and was enriched in advanced-stage tumors and those harboring oncogenic drivers, including EGFR mutations, ALK fusions, and MET and ERBB2 amplifications; co-deletion with CDKN2A was highly prevalent at 92.3%. In driver-positive patients, MTAP loss was associated with significantly lower response rate and shorter PFS and OS, especially in EGFR-mutant patients treated with third-generation EGFR-TKIs.

Clinical bottom line: MTAP loss is a robust adverse prognostic biomarker in EGFR-mutant NSCLC on targeted therapy, supporting its integration into risk stratification and combination strategies with PRMT5 or MAT2A inhibition.

Read full article →

Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320). — Bozorgmehr Farastuk et al., JAMA Oncol

Median OS in the combination arm was numerically shorter than with atezolizumab alone (6.7 months [95% CI, 5.1–9.0] vs 13.4 months [95% CI, 10.7–17.5]; HR 1.55 [95% CI, 0.90–2.69]; P=.34), while median PFS was similar (2.4 months [95% CI, 1.3–3.9] vs 2.6 months [95% CI, 1.2–3.9]; HR 0.92 [95% CI, 0.54–1.55]; P=.85). Adding thoracic radiotherapy was accompanied by higher frequency of severe adverse events (61.3% vs 18.2%; P<.001) and fatal outcomes (19.4% vs 3.0%; P=.04).

Clinical bottom line: Consolidative thoracic radiotherapy added to atezolizumab maintenance in unselected ES-SCLC increased toxicity and deaths without any survival benefit, so it should not be applied broadly.

Read full article →

Lung Transplant for Refractory Lung-Limited Stage IV Non-Small Cell Lung Cancer. — Bharat Ankit et al., JAMA

The Kaplan-Meier estimated 1-year overall survival was 100.0% (95% CI, 63.1%–100.0%) among lung transplant recipients with NSCLC versus 40.8% (95% CI, 29.6%–53.1%) among those who received medical management alone, an absolute difference of 59.2 (95% CI, 46.2–71.7) percentage points. The 1-year posttransplant survival was 100% (95% CI, 63.1%–100%) among patients with NSCLC versus 88.1% (95% CI, 83.7%–91.4%) among patients without cancer, an absolute difference of 11.9 (90% CI, 9.1–15.5) percentage points.

Clinical bottom line: In a rigorously selected subset of medically refractory, lung-limited stage IV NSCLC with respiratory failure, lung transplant using a dissemination-minimizing technique delivered favorable early survival that challenges the historical exclusion of these patients.

Read full article →

Weight Gain on Lorlatinib is Associated with Accumulation of Visceral Adipose Tissue. — Mantz Lea et al., J Thorac Oncol

In 67 patients, skeletal muscle index, visceral adipose tissue index, and BMI increased from baseline to 3 months and from 3 months to 6 months; the baseline-to-3-month visceral adipose tissue index rise was 4.23 cm²/m² (95% CI 2.37–6.19; p<.001) and BMI increased by 0.97 kg/m² (95% CI 0.59–1.35; p<.001).

Clinical bottom line: Lorlatinib-associated weight gain is preferentially visceral adiposity, so interventions should target visceral fat.

Read full article →

Real-World Implementation of Tarlatamab-Dlle Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Other High-Grade Neuroendocrine Neoplasms. — Carlisle Jennifer W et al., JCO Oncol Pract

Among 49 outpatient SCLC patients with a median follow-up of 6.94 months (95% CI, 5.03–11.34), the estimated median PFS was 3.7 months (95% CI, 2.7–5.2) and median OS was 7.1 months (95% CI, 4.9–9.3). Grade 3 CRS occurred in two patients (4.1%) and grade 3 ICANS in three patients (6.1%).

Clinical bottom line: Outpatient tarlatamab administration for relapsed SCLC is safe and feasible with appropriate monitoring in an on-site immediate care setting.

Read full article →

Germline Mutations as Risk Factors for Lung Cancer: A Systematic Review and Meta-analysis. — Lee Ji Young et al., J Thorac Oncol

The pooled prevalence of pathogenic or likely pathogenic germline variants was 7.9% (95% CI, 3.8–15.9%) with high heterogeneity (I²=98.8%).

Clinical bottom line: Roughly 8% of lung cancer patients carry pathogenic germline variants, most often in DNA damage repair genes, with higher frequencies in younger patients and non-Asian ancestry.

Read full article →

Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431. — Cui Can et al., J Thorac Oncol

Median PFS by blinded independent central review was 11.2 months (95% CI: 10.9–16.8) with chemoimmunotherapy versus not reached (95% CI: 4.9–not reached) with chemotherapy; the difference was not statistically significant (p=0.8). These findings indicate that adding a checkpoint inhibitor to chemotherapy did not improve outcomes over chemotherapy alone in this biomarker-selected population.

Clinical bottom line: Adding a checkpoint inhibitor to chemotherapy did not improve outcomes over chemotherapy alone in RET fusion-positive lung cancer, and selective RET inhibitors remain the preferred first-line therapy.

Read full article →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

ARTEMIS-008: first phase 3 OS win for a B7-H3 ADC in relapsed SCLC

GSK announced positive results from the phase III ARTEMIS-008 trial showing that risvutatug rezetecan, a B7-H3 ADC, demonstrated superior overall survival versus topotecan in patients with relapsed SCLC — marking the first phase 3 OS win for a B7-H3 ADC. Oncologists debating the full dataset noted a continuing preference for tarlatamab in this setting, while the China-only trial population raises the question of how applicable ARTEMIS-008 is to Western standard of care relative to tarlatamab and the global EMBOLD trial.

Discussed by: @StephenVLiu, @DrSanjayPopat, @g_mountzios

→ View representative tweet

Update: PACIFIC post-hoc pulls in editorial voices on PPIs, antibiotics and the gut microbiome

The PACIFIC post-hoc analysis showed that, in the durvalumab group, baseline PPI use was associated with shorter PFS (9.4 months vs 17.2 months with no PPI; HR 1.57) and shorter OS (33 months vs 57.9 months; HR 1.66), with no corresponding difference in the placebo arm and similar PFS findings observed with antibiotics. An accompanying editorial argues that prospective studies with standardised exposure definitions and trial-embedded interventions are required to translate findings on microbiota-modifying medications in locally advanced NSCLC into actionable practice, leaving unresolved whether baseline PPI and antibiotic use should be actively minimized in patients starting durvalumab after concurrent chemoradiotherapy.

Discussed by: @StephenVLiu, @Dr_ElvinaA, @Latinamd

→ View representative tweet

ELEVATE: adjuvant ensartinib matches ALINA-level DFS in resected ALK+ NSCLC

In the stage II–IIIB population, 24-month DFS was 86.4% with ensartinib versus 53.5% with placebo (HR 0.20; 95% CI, 0.11–0.38; P<0.001), with the overall population showing 87.3% versus 57.2% at the same HR of 0.20 — described by clinicians as the same striking HR as ALINA. Grade ≥3 adverse events were 35.8% versus 18.2%, predominantly rash, while OS remains immature; debate centers on whether this ALINA-like DFS benefit justifies routine two-year adjuvant ALK inhibition after chemotherapy and how molecular testing should be integrated into early-stage NSCLC workup.

Discussed by: @StephenVLiu, @YGaritaonaindia, @HHorinouchi

→ View representative tweet

DREAM: lung transplant offers striking early survival in refractory lung-limited stage IV NSCLC

The Kaplan-Meier estimated 1-year overall survival was 100% in the lung transplant group versus 40.8% for those who received medical management alone — a striking absolute difference of 59.2 percentage points — in a rigorously selected population with refractory lung-limited stage IV NSCLC. Lung transplant following contemporary staging and a dissemination-minimizing surgical technique was associated with higher early overall survival compared with medical management alone, though the question remains how this single-center DREAM registry experience can be scaled and confirmed given that nonbiologic barriers limited transplant access in most eligible patients.

Discussed by: @christinemphmd, @JAMA_current

→ View representative tweet

Ifebemtinib plus garsorasib delivers high response in first-line KRAS G12C NSCLC

A study of first-line ifebemtinib (a FAK inhibitor) plus garsorasib (a KRAS G12C inhibitor) in KRAS G12C NSCLC, published in The Lancet Respiratory Medicine, reported a response rate of 82%, median PFS of 22.3 months, and median OS of 27.8 months, with 24% of patients experiencing grade 3 or higher treatment-related adverse events including proteinuria, diarrhea, anemia, hypertension, and pneumonia. Clinicians noted encouraging signals despite small numbers, with the central debate being whether a FAK inhibitor plus KRAS G12C inhibitor combination can move first-line KRAS G12C NSCLC beyond single-agent inhibition.

Discussed by: @StephenVLiu, @newsen.bsky.social

→ View representative tweet

TREASURE: consolidative thoracic radiotherapy adds toxicity without survival in ES-SCLC

In the TREASURE trial, median OS was numerically shorter with the combination of thoracic radiotherapy plus atezolizumab versus atezolizumab alone (6.7 months vs 13.4 months; HR 1.55; 95% CI, 0.90–2.69), median PFS showed no difference (2.4 months vs 2.6 months; HR 0.92), and severe adverse events were markedly more frequent (61.3% vs 18.2%) with fatal events in 19.4% versus 3.0%. With both TREASURE and TRIPLEX demonstrating added toxicity from thoracic radiotherapy in ES-SCLC, clinicians are debating whether any role remains for consolidative radiotherapy outside carefully selected patients.

Discussed by: @YGaritaonaindia, @OncoAlert

→ View representative tweet

🔥 Top Ranked Tweets

Vivek Subbiah, MD @VivekSubbiah

⭐️Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | New England Journal of Medicine https://t.co/lJc0Kne6Yr

🔖 3 ❤️ 11 🔁 3 👁 1,777